Frontiers in Oncology (Feb 2021)
Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2
- Dristhi Ragoonanan,
- Sajad J. Khazal,
- Rodrigo Mejia,
- Linette Ewing,
- Jean-Bernard Durand,
- Lara Bashoura,
- Jean Tayar,
- Natalie Dailey Garnes,
- Demetrios Petropoulos,
- Priti Tewari,
- Micah Bhatti,
- Ali Haider Ahmad,
- Jose Cortes,
- Shehla Razvi,
- Katrina McBeth,
- Rita Swinford,
- Basirat Shoberu,
- Waseem Waseemuddin,
- Linda Chi,
- Jonathan B. Gill,
- Wafik Zaky,
- Najat Daw,
- Cristina Gutierrez,
- Welela Tereffe,
- Partow Kebriaei,
- Katayoun Rezvani,
- Elizabeth J. Shpall,
- Richard E. Champlin,
- Kris M. Mahadeo
Affiliations
- Dristhi Ragoonanan
- Pediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Sajad J. Khazal
- Pediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Rodrigo Mejia
- Pediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Linette Ewing
- Pediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Jean-Bernard Durand
- Department of Cardiology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Lara Bashoura
- Department of Pulmonary Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Jean Tayar
- Department of Rheumatology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Natalie Dailey Garnes
- Department of Infectious Disease, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Demetrios Petropoulos
- Pediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Priti Tewari
- Pediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Micah Bhatti
- Department of Pathology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Ali Haider Ahmad
- Pediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Jose Cortes
- Pediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Shehla Razvi
- Pediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Katrina McBeth
- Department of Pediatric Pulmonary Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Rita Swinford
- Department of Pediatric Nephrology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Basirat Shoberu
- Pediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Waseem Waseemuddin
- Pediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Linda Chi
- 0Department of Neuroradiology, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Jonathan B. Gill
- 1Department of Pediatric Oncology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Wafik Zaky
- 1Department of Pediatric Oncology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Najat Daw
- 1Department of Pediatric Oncology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Cristina Gutierrez
- 2Department of Critical Care Medicine, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Welela Tereffe
- 3University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Partow Kebriaei
- 4Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Katayoun Rezvani
- 4Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Elizabeth J. Shpall
- 4Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Richard E. Champlin
- 4Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- Kris M. Mahadeo
- Pediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States
- DOI
- https://doi.org/10.3389/fonc.2021.625707
- Journal volume & issue
-
Vol. 11
Abstract
Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administration and review evolving characterization of both the natural course of SARS-CoV-2 infection and toxicities experienced in younger cancer immunotherapy patients. Vigilant monitoring for unique presentations and epidemiologic surveillance to promptly detect changes in incidence of either condition may be warranted.
Keywords
